Application of IL-37 inhibitor in preparation of medicine for treating hyperpigmentation dermatosis

The invention provides application of an IL-37 inhibitor in preparation of a medicine for treating hyperpigmentation dermatosis. Experimental results show that after human pigment cells and skin are treated by IL-37, the melanin content is obviously increased, the expression levels of melanin generation key genes MITF, TYR, TYRP1 and DCT are also obviously increased, and meanwhile, the tyrosinase activity is also obviously enhanced. Research results indicate that IL-37 is a key inflammatory factor for regulating melanogenesis and can be used as a candidate therapeutic drug or a therapeutic target for hyperpigmentation dermatosis. 本发明提供了IL-37的抑制剂在制备治疗色素沉着增多性皮肤病药物中的应用。本发明的实验结果发现IL-37处理人色素细胞和皮肤后，其黑素含量明显增多，黑素生成关键基因MITF、TYR、TYRP1、DCT的表达水平也显著上调，同时酪氨酸酶活性也显著增强。本研究结果提示IL-37是调控黑素生成的关键炎症因子，可以作为色素沉着增多性皮肤病的候选治疗药物或治疗靶点。